PROGRAM OVERVIEW

Dr. Richard M. Goldberg moderates a discussion with gastrointestinal stromal tumor (GIST) experts, Charles D. Blanke, MD, and Margaret von Mehren, MD, who present and discuss the case of a 64-year-old woman with metastatic GIST. Through this case, they illustrate how current diagnosis is informed by recent knowledge of the oncogenesis of GIST. They also talk about the implications of new data with regard to selecting and optimizing targeted therapies for first- and second-line treatment in metastatic disease. Emerging concepts such as adjuvant treatment with targeted therapies, use of genotyping to tailor dosing, and prevention and management of resistance to targeted therapies are explored. Throughout, you will be provided with the opportunity to add your own input on appropriate management and compare your answers with those of your colleagues.

• Case Study of a 64-Year-Old Woman With Metastatic GIST
• Molecular Oncogenesis
• Primary Treatment With Targeted Therapy
• Tailoring Dose According to Genotype
• Use of Targeted Therapies in Adjuvant and Neoadjuvant Treatment of Earlier Disease
• Prevention and Treatment of Resistance to Targeted Therapies
• Second-Line and Investigational Therapies for GIST

top

TARGET AUDIENCE

This CME activity is directed to medical oncologists, gastroenterologists, and other healthcare professionals who provide care to patients with gastrointestinal stromal tumors.

ACTIVITY GOAL

The goal of this CME activity is to present the molecular basis for targeted therapies and clinical strategies for their management in the treatment of gastrointestinal stromal tumors. Current therapeutic options and outcomes will be illustrated through case studies.

top

LEARNING OBJECTIVES

• Distinguish the mechanism of action, and prognostic and treatment implications of current and emerging targeted therapies in accordance with the most recent medical literature regarding the molecular basis of oncogenesis in gastrointestinal stromal tumors (GIST)
  
  
• Formulate optimal treatment strategies that maximize response and survival rates for individual patients with GIST based on the patient's molecular profile and an understanding of the mechanisms of action, efficacy, and safety of current and emerging targeted therapies
  
  
• Integrate practical approaches to the management of side effects for GIST patients taking targeted therapies in order to maintain patients with GIST on optimal therapy
  

top

CME INFORMATION

Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contract for Mutual Responsibility in CME
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience. For more information on the contract, click here.

top

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Charles D. Blanke, MD, has received grants and research contracts from Novartis Pharmaceuticals Corporation.

Margaret von Mehren, MD, has received grant/research support from Novartis Pharmaceuticals Corporation and Pfizer Inc; is a consultant for MedImmune, Inc, Novartis Pharmaceuticals Corporation and Pfizer Inc; is on the speakers bureau of Novartis Pharmaceuticals Corporation; and is on the advisory boards of MedImmune, Inc and Novartis Pharmaceuticals Corporation.

Richard M. Goldberg, MD, has received grant/research support from Pfizer Inc; and is a consultant for ALMAC Group Ltd, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Genentech, Inc, Genomic Health, Inc, ImClone Systems Inc, Sanofi-Aventis, Taiho Pharmaceutical Company Ltd, and Yakult.

Peer Reviewer has received grant/research support from AstraZeneca; and has received speaker honoraria from the New York Academy of Sciences (NYAS).

Projects In Knowledge’s staff members have no significant relationships to disclose.

This activity will include discussion of unlabeled/unapproved uses of chemotherapy regimens, dasatinib, adjuvant and neoadjuvant imatinib, imatinib administered at a dose of 800 mg/d for patients with exon 9 mutations, midostaurin, motasenib, nilotinib, oblimersen, rapamycin, retaspimycin, sorafenib, and continuous daily dosing of sunitinib.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.

top

Requires Flash 8 or higher
and high-speed internet